Legal & General Group
SLN

Legal & General Group’s Silence Therapeutics SLN Stock Holding History

Legal & General Group’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-14,973
Closed -$288K – 3642
2022
Q1 		$288K Buy
+14,973
New +$298K ﹤0.01% 2549

Other funds holding SLN

LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Legal & General Group's SLN Position: Q2 2022 in Review

Legal & General Group sold out of Silence Therapeutics (SLN) in Q2 2022, closing a stake of 14,973 shares — an estimated $288K sold.

Legal & General Group first reported a position in SLN in Q1 2022 and held it in 1 quarter. The position peaked at $288K in Q1 2022. 25 funds tracked by Wall St. Rank hold SLN as of Q2 2022.

  • Legal & General Group reported no remaining Silence Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Legal & General Group sold 14,973 Silence Therapeutics shares in Q2 2022, an estimated $288K.
  • Legal & General Group first reported a position in Silence Therapeutics in Q1 2022 and held it in 1 quarter.
  • Legal & General Group's Silence Therapeutics position peaked at $288K in Q1 2022.
  • 25 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2022.

Based on Legal & General Group's 13F filing for Q2 2022, filed 22 Aug 2022.